Aandelen in “Farmaceutische Producten: Generisch”

Aandeel Datum Koers Evolutie
vlag Lifevantage Corporation 22/10 8,670 USD
+0,46% 		+0,46%

Nieuws over “Farmaceutische Producten: Generisch”

20/10 · Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe · Persbericht

20/10 · Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe · Persbericht

10/10 · FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder · Persbericht

1/10 · Europese Commissie opent mededingingsonderzoek naar griepvaccins bij Sanofi · Bolero.be

Sanofi bevestigt dat de Europese mededingingsautoriteiten invallen hebben gedaan in kantoren in Frankrijk en Duitsland. De Europese Commissie onderzoekt mogelijke misleidende communicatie over concurrenten in de griepvaccinmarkt,...

25/09 · Teva Releases Q3 2025 Aide Memoire · Persbericht

25/09 · Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025 · Persbericht

21/09 · Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction · Persbericht

21/09 · New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed · Persbericht

16/09 · Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting · Persbericht

9/09 · Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy · Persbericht

2/09 · Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September · Persbericht

28/08 · Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss · Persbericht

25/08 · Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) · Persbericht

25/08 · Nieuw bedrijf in de opvolging bij KBC Securities Global Equities: Deckers Outdoor · Bolero.be

Deckers Outdoor? Deckers Outdoor,  opgericht in 1973 in Californië, is een Amerikaans schoenen- en kledingbedrijf dat zich richt op premium lifestyle- en sportmerken. De groep bezit vier merken, waarvan UGG en HOKA veruit...

6/08 · FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine · Persbericht

30/07 · Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components · Persbericht

Mijn selecties